<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669903</url>
  </required_header>
  <id_info>
    <org_study_id>D0190C00007</org_study_id>
    <nct_id>NCT00669903</nct_id>
  </id_info>
  <brief_title>Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia</brief_title>
  <official_title>A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Oral Multiple Ascending Doses of AZD0328 in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of
      multiple ascending doses of AZD0328 in patients with schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to
    stop further development of AZD0328
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CogState Groton Maze Learning Task (GMLT) and One Card Learning Task (OCLT) Standardized Composite Score at Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>The GMLT and OCLT standardized change composite score will be calculated as the mean of the GMLT and OCLT standardized change from baseline scores. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CogState Groton Maze Learning Task (GMLT) Standardized Change Score at Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>GMLT score is defined as the -log10 transform of the sum of the number of errors made during GMLT trials. Mean GMLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMLT standardized change score was calculated as the change from baseline in the mean GMLT score divided by the within subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CogState One Card Learning Task (OCLT) Standardized Change Score at Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>OCLT score is defined as the arcsine transform of the proportion of correct responses during OCLT trials. Mean OCLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The OCLT standardized change score was calculated as the change from baseline in the mean OCLT score divided by the within-subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CogState Detection Task (DT) Standardized Change Score at Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>DT score is defined as -1 times the mean of log10 transformed reaction times for all correct responses. Mean DT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The DT standardized change score will be calculated as the change from baseline in the mean DT score divided by the within-subject standard deviation. Score range from negative infinity (worst value) to positive infinity (best value).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CogState Identification Task (IT) Standardized Change Score at Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>IT score defined as 1 times the mean of log10 transformed reaction times for all correct responses. Mean IT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The IT standardized change score will be calculated as the change from baseline in the mean IT score divided by the within-subject standard dev. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CogState Groton Maze Recall Task (GMRT) Standardized Change Score at Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>GMRT score defined as the -log10 transform of the sum of the number of errors made during GMRT trials. Mean GMRT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMRT standardized change score was calculated as change from baseline in mean GMRT score divided by the within subject standard deviation. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, assessment day-by-treatment interaction as fixed factors, center as random factor, and baseline score as a covariate</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0328 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0328 Optimal dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0328 High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0328</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia according to the DSM-IV (Diagnostic and Statistical Manual
             of Mental Disorders, 4th Edition)

          -  Low level of Extra-pyramidal symptoms

          -  No clinically significant findings on physical examination

        Exclusion Criteria:

          -  Diagnosis of schizoaffective or schizophreniform disorders

          -  Any significant psychiatric or neurological disease other than schizophrenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <results_first_submitted>February 4, 2010</results_first_submitted>
  <results_first_submitted_qc>July 9, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2010</results_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Didier Meulien - Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of two US centers were inititated with first patient enrolled on 2 April 2008 and last patient completed on 4 November 2008. A total of 158 patients were enrolled with 100 patients allocated to randomized treatment.</recruitment_details>
      <pre_assignment_details>Patients were to receive a stable dose of an antipsychotic for the 4 weeks prior to randomization, have stable psychotic symptoms without a hospitalization for the 8 weeks prior to randomization, and were to be smoking an average of &gt;=10 cigarettes per day. Enrolled patients who no longer met entry criteria at randomization were not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD0328 Low Dose Group</title>
          <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
        </group>
        <group group_id="P2">
          <title>AZD0328 Optimal Dose Group</title>
          <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
        </group>
        <group group_id="P3">
          <title>AZD0328 High Dose Group</title>
          <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD0328 Low Dose Group</title>
          <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
        </group>
        <group group_id="B2">
          <title>AZD0328 Optimal Dose Group</title>
          <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
        </group>
        <group group_id="B3">
          <title>AZD0328 High Dose Group</title>
          <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="11.2"/>
                    <measurement group_id="B2" value="41.7" spread="9.2"/>
                    <measurement group_id="B3" value="38.3" spread="9.8"/>
                    <measurement group_id="B4" value="40.0" spread="9.8"/>
                    <measurement group_id="B5" value="40.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Positive and Negative Syndrome Scale (PANSS) total score</title>
          <description>Baseline Positive and Negative Syndrome Scale (PANSS) total score. Best value for PANSS total score = 30 to worse value for PANSS total score = 210</description>
          <units>Points of PANSS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" spread="10.3"/>
                    <measurement group_id="B2" value="71.8" spread="12.0"/>
                    <measurement group_id="B3" value="72.1" spread="12.2"/>
                    <measurement group_id="B4" value="69.5" spread="13.2"/>
                    <measurement group_id="B5" value="70.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CogState Groton Maze Learning Task (GMLT) and One Card Learning Task (OCLT) Standardized Composite Score at Day 14</title>
        <description>The GMLT and OCLT standardized change composite score will be calculated as the mean of the GMLT and OCLT standardized change from baseline scores. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
        <time_frame>Baseline and Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0328 Low Dose Group</title>
            <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
          </group>
          <group group_id="O2">
            <title>AZD0328 Optimal Dose Group</title>
            <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
          </group>
          <group group_id="O3">
            <title>AZD0328 High Dose Group</title>
            <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CogState Groton Maze Learning Task (GMLT) and One Card Learning Task (OCLT) Standardized Composite Score at Day 14</title>
          <description>The GMLT and OCLT standardized change composite score will be calculated as the mean of the GMLT and OCLT standardized change from baseline scores. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.234" spread="0.122" lower_limit="0.122"/>
                    <measurement group_id="O2" value="0.240" spread="0.072" lower_limit="0.072"/>
                    <measurement group_id="O3" value="0.194" spread="0.216" lower_limit="0.216"/>
                    <measurement group_id="O4" value="0.266" spread="0.099" lower_limit="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CogState Groton Maze Learning Task (GMLT) Standardized Change Score at Day 14</title>
        <description>GMLT score is defined as the –log10 transform of the sum of the number of errors made during GMLT trials. Mean GMLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMLT standardized change score was calculated as the change from baseline in the mean GMLT score divided by the within subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
        <time_frame>Baseline and Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0328 Low Dose Group</title>
            <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
          </group>
          <group group_id="O2">
            <title>AZD0328 Optimal Dose Group</title>
            <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
          </group>
          <group group_id="O3">
            <title>AZD0328 High Dose Group</title>
            <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CogState Groton Maze Learning Task (GMLT) Standardized Change Score at Day 14</title>
          <description>GMLT score is defined as the –log10 transform of the sum of the number of errors made during GMLT trials. Mean GMLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMLT standardized change score was calculated as the change from baseline in the mean GMLT score divided by the within subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.313" spread="0.163" lower_limit="0.163"/>
                    <measurement group_id="O2" value="0.360" spread="0.104" lower_limit="0.104"/>
                    <measurement group_id="O3" value="0.281" spread="0.249" lower_limit="0.249"/>
                    <measurement group_id="O4" value="0.235" spread="0.124" lower_limit="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CogState One Card Learning Task (OCLT) Standardized Change Score at Day 14</title>
        <description>OCLT score is defined as the arcsine transform of the proportion of correct responses during OCLT trials. Mean OCLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The OCLT standardized change score was calculated as the change from baseline in the mean OCLT score divided by the within-subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
        <time_frame>Baseline and Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0328 Low Dose Group</title>
            <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
          </group>
          <group group_id="O2">
            <title>AZD0328 Optimal Dose Group</title>
            <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
          </group>
          <group group_id="O3">
            <title>AZD0328 High Dose Group</title>
            <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CogState One Card Learning Task (OCLT) Standardized Change Score at Day 14</title>
          <description>OCLT score is defined as the arcsine transform of the proportion of correct responses during OCLT trials. Mean OCLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The OCLT standardized change score was calculated as the change from baseline in the mean OCLT score divided by the within-subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" spread="0.126" lower_limit="0.126"/>
                    <measurement group_id="O2" value="0.102" spread="0.100" lower_limit="0.100"/>
                    <measurement group_id="O3" value="0.094" spread="0.232" lower_limit="0.232"/>
                    <measurement group_id="O4" value="0.316" spread="0.152" lower_limit="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CogState Detection Task (DT) Standardized Change Score at Day 14</title>
        <description>DT score is defined as -1 times the mean of log10 transformed reaction times for all correct responses. Mean DT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The DT standardized change score will be calculated as the change from baseline in the mean DT score divided by the within-subject standard deviation. Score range from negative infinity (worst value) to positive infinity (best value).</description>
        <time_frame>Baseline and Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0328 Low Dose Group</title>
            <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
          </group>
          <group group_id="O2">
            <title>AZD0328 Optimal Dose Group</title>
            <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
          </group>
          <group group_id="O3">
            <title>AZD0328 High Dose Group</title>
            <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CogState Detection Task (DT) Standardized Change Score at Day 14</title>
          <description>DT score is defined as -1 times the mean of log10 transformed reaction times for all correct responses. Mean DT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The DT standardized change score will be calculated as the change from baseline in the mean DT score divided by the within-subject standard deviation. Score range from negative infinity (worst value) to positive infinity (best value).</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" spread="0.116" lower_limit="0.116"/>
                    <measurement group_id="O2" value="-0.014" spread="0.115" lower_limit="0.115"/>
                    <measurement group_id="O3" value="-0.095" spread="0.158" lower_limit="0.158"/>
                    <measurement group_id="O4" value="0.098" spread="0.095" lower_limit="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CogState Identification Task (IT) Standardized Change Score at Day 14</title>
        <description>IT score defined as 1 times the mean of log10 transformed reaction times for all correct responses. Mean IT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The IT standardized change score will be calculated as the change from baseline in the mean IT score divided by the within-subject standard dev. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate</description>
        <time_frame>Baseline and Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0328 Low Dose Group</title>
            <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
          </group>
          <group group_id="O2">
            <title>AZD0328 Optimal Dose Group</title>
            <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
          </group>
          <group group_id="O3">
            <title>AZD0328 High Dose Group</title>
            <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CogState Identification Task (IT) Standardized Change Score at Day 14</title>
          <description>IT score defined as 1 times the mean of log10 transformed reaction times for all correct responses. Mean IT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The IT standardized change score will be calculated as the change from baseline in the mean IT score divided by the within-subject standard dev. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate</description>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.145" spread="0.177" lower_limit="0.177"/>
                    <measurement group_id="O2" value="-0.049" spread="0.121" lower_limit="0.121"/>
                    <measurement group_id="O3" value="-0.173" spread="0.136" lower_limit="0.136"/>
                    <measurement group_id="O4" value="-0.103" spread="0.132" lower_limit="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CogState Groton Maze Recall Task (GMRT) Standardized Change Score at Day 14</title>
        <description>GMRT score defined as the –log10 transform of the sum of the number of errors made during GMRT trials. Mean GMRT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMRT standardized change score was calculated as change from baseline in mean GMRT score divided by the within subject standard deviation. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, assessment day-by-treatment interaction as fixed factors, center as random factor, and baseline score as a covariate</description>
        <time_frame>Baseline and Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0328 Low Dose Group</title>
            <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
          </group>
          <group group_id="O2">
            <title>AZD0328 Optimal Dose Group</title>
            <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
          </group>
          <group group_id="O3">
            <title>AZD0328 High Dose Group</title>
            <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CogState Groton Maze Recall Task (GMRT) Standardized Change Score at Day 14</title>
          <description>GMRT score defined as the –log10 transform of the sum of the number of errors made during GMRT trials. Mean GMRT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMRT standardized change score was calculated as change from baseline in mean GMRT score divided by the within subject standard deviation. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, assessment day-by-treatment interaction as fixed factors, center as random factor, and baseline score as a covariate</description>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.213" spread="0.139" lower_limit="0.139"/>
                    <measurement group_id="O2" value="0.406" spread="0.112" lower_limit="0.112"/>
                    <measurement group_id="O3" value="0.467" spread="0.263" lower_limit="0.263"/>
                    <measurement group_id="O4" value="0.409" spread="0.183" lower_limit="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD0328 Low Dose Group</title>
          <description>AZD0328 Low dose group (0.00093 to 0.0028 mg oral solution)</description>
        </group>
        <group group_id="E2">
          <title>AZD0328 Optimal Dose Group</title>
          <description>AZD0328 Optimal dose group (0.0048 to 0.0329 mg oral solution)</description>
        </group>
        <group group_id="E3">
          <title>AZD0328 High Dose Group</title>
          <description>AZD0328 High dose group (0.075 to 0.675 mg oral solution)</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication or presentation of results until the earlier of the publication of the first multi-center publication and the second anniversary of the completion of the multi-center study at all sites. Sponsor must receive a copy of proposed manuscript for review and comment at least 60 days prior to its submission for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

